COVID-19 & Psychiatry: A Retrospective Chart Review

A Retrospective Chart Review Study to Determine the Effects of Psychotropic Medications and Prior Psychiatric Diagnoses on COVID-19 Patients' Disease Progression, and Severity.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05244096

Enrollment

65000

Registered

2022-02-17

Start date

2022-01-12

Completion date

2025-03-30

Last updated

2024-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

A retrospective chart review study to determine the effects of psychotropic medications and prior psychiatric diagnoses on COVID-19 patients' disease progression, and severity.

Detailed description

The goal of this study would be to study the association between use of psychotropic medications and prior psychiatric diagnoses on COVID-19 patients' disease progression and severity.

Interventions

OTHERNo intervention

Observational study

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- Individuals with a positive COVID-19 test between March 15 2020 to November 30 2021 at Northwestern Medicine hospitals.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Hazard Ratio	March 15 2020 to Nov 30 2021	HR of using psych drugs or having psych diagnosis

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026